

Genomic insights of high-risk clones of ESBL-producing *Escherichia coli* isolated from community infections and commercial meat in Southern Brazil

João Gabriel Material Soncini¹, Louise Cerdeira², Vanessa Lumi Koga³, Ariane Tiemy Tizura¹, Bruna Fuga⁵, Gerson Nakazato³, Renata Katsuko Takayama Kobayashi³, Caio Augusto Martins Aires⁴, Nilton Lincopan⁵, Eliana Carolina Vespero^{1*}

¹ Laboratory of Clinical Microbiology, Department of Pathology, Clinical and Toxicological Analysis, Health Sciences Center, State University of Londrina, Londrina, Brazil

² Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia

³ Department of Microbiology, Biological Science Center, State University of Londrina, Londrina, Brazil

⁴ Department of Health Science, Health and Biological Science Center, Federal Rural University of Semi-Arid, Mossoró, Brazil.

⁵ Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Brazil.

*eliana.vespero@gmail.com

Keywords: *Escherichia coli*, EPEC, one health, WGS, food-producing, ST131, ST648, resistome.

ABSTRACT

During a microbiological and genomic surveillance study to investigate the molecular epidemiology of extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* from community-acquired urinary tract infections (UTI) and commercial meat samples, in a Brazilian city with a high occurrence of infections by ESBL-producing bacteria, we have identified the presence of CTX-M (-55, -27, -24, -15, -14 and -2)-producing *E. coli* belonging to the international clones ST354, ST131, ST117, and ST38. The ST131 was more prevalent in human samples, and worryingly the high-risk ST131-C1-M27 was identified in human infections for the first time. We also detected CTX-M-55-producing *E. coli* ST117 isolates from meat samples (i.e., chicken and pork) and human infections. Moreover, we have identified the important clone CTX-M-24-positive *E. coli* ST354 from human samples in Brazil for the first time. In brief, our results suggest a potential of commercialized meat as a reservoir of high-priority *E. coli* lineages in the community. In contrast, the identification of *E. coli* ST131-C1-M27 indicates that novel pandemic clones have emerged in Brazil, constituting a public health issue.

INTRODUCTION

Escherichia coli is a commensal of the human intestinal tract and most warm-blooded mammals and figures as an important pathogen for humans and animals^{1,2}. In humans, urinary tract infection (UTI) is the second most common bacterial infection managed in primary care, and uropathogenic *E. coli* (UPEC) is responsible for 75% to 95% of the cases¹. The increasing antimicrobial resistance (AMR) detected in clinical UPEC isolates has been of concern¹ and infections caused by antimicrobial-resistant bacteria as extended-spectrum β -lactamase (ESBL)-producing *E. coli* represent significant healthcare issues² since it compromises the effective treatment, being responsible for a large number of morbidity and mortality³.

Since *E. coli* can act as a large reservoir of resistance genes that directly impact treatment in human and veterinary medicine, the debate over the transmission of multiresistant *E. coli* strains between animals and humans through numerous pathways has become increasingly important. However, the interaction between food-producing animals, humans, and the environment regarding the transmission of these resistant pathogens is not yet fully understood^{2,4}.

The isolation of ESBL-producing *E. coli* from food-production animals is increased worldwide, mostly from chicken meat^{2,4}. The excessive use of antimicrobials in livestock is one of the practices that help in the emergence of pathogens resistant to humans. The consumption of meat, direct contact with colonized animals, or manure spread in the environment are sources for the transmission of livestock AMR to humans⁵⁻⁷. Besides that, AMR gene transfer may occur between different bacterial species in the gut of animals and humans⁸.

The CTX-M type is one of the largest groups of ESBL, and recent studies that addressed the epidemiology of these enzymes in Brazil, show that CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-15 are the predominant variants in the country⁹⁻¹¹. Many types of CTX-M-producing *E. coli* have been recognized as belonging to specific clones commonly isolated from UTI cases originating in a particular locale, country, or even globally. Some studies show that isolates from foods CTX-M genotypes sometimes correspond with the locally dominant human types^{12,13}

Considering the emerging AMR in Brazil, both in human medicine as in livestock, and the need for understanding this panorama, we conducted next-generation sequencing (NGS)-based analysis adopting a One Health approach to assess national transmission of CTX-M-producing *E. coli* isolated from meat products and human patients.

RESULTS

The results for each of 91 *E. coli* isolates included in this study can be seen in **Figure 1** (<https://doi.org/10.6084/m9.figshare.13471044.v1>). It is notorious high rates of resistance to ampicillin (100%), ceftriaxone (87.91%), nalidixic acid (87.91%), cefepime (83.52%), trimethoprim-sulfamethoxazole (82.42 %), nitrofurantoin (76.92%), norfloxacin (75.82%) and ciprofloxacin (72.53%). Less than half showed resistance to gentamicin (36.26%) and amoxicillin/clavulanate (21.98%). Only three (3.30%) isolates were resistant to piperacillin-tazobactam and two (2.20%) to amikacin. Some isolates also showed intermediate resistance levels: 28.57% to amoxicillin/clavulanate; 4.40% to piperacillin-tazobactam and gentamicin; 1.10% to ciprofloxacin and norfloxacin.

Genomic analysis revealed 57 genes associated with resistance to aminoglycosides (n = 15), β -lactams (n = 12), trimethoprim (n = 8), phenicols (n = 5), tetracyclines (n = 4), macrolides (n = 4), sulfonamides (n = 3), quinolones (n = 3), lincosamides (n = 2) and fosfomycin (n = 1). Regarding aminoglycosides, the most prevalent genes were *strA* and *strB*, both with 39.56%, followed by the *aadA1* gene (36.26%). The *dfrA17* and *dfrA1* genes, associated with resistance to trimethoprim, were detected in 31 (34.07%) and 13 (14.29%) isolates, respectively. Genes related to phenicols resistance had similar prevalence, being *catB3* (8.79%), *floR* (5.49%), *catA1* (4.40%) and *cmlA1* (4.40%). Concerning to tetracyclines resistance, we detected the *tet(A)* (38.46%) and *tet(B)* (27.47%) genes. About macrolides the *mph(A)* gene (29.67%) was found and the detected genes related to sulfonamides were *sul1* (56.04%) and *sul2* (53.85%). Few isolates had lincosamide resistance genes, two of them had *Inu(F)* (2.20%) and one *Inu(A)* (1.10%). The *fosA* gene found in three isolates was the only one associated with fosfomycin resistance.

The genes associated with resistance to β -lactams were *bla*_{TEM-1B} (48.35%), *bla*_{OXA-1} (7.69%), *bla*_{CMY-2} (6.59%), and *bla*_{TEM-1A} (2.20%), in addition to eight variants of the *bla*_{CTX-M} gene that encode CTX-M-type ESBL enzymes. Among the ESBL coding genes, *bla*_{CTX-M-55} was the most detected (21.98%), mainly from chicken meats (n = 10), followed by humans (n = 6) and porks (n = 4). The *bla*_{CTX-M-15} was found predominantly in human isolates (n = 14) and only in one pork isolate. On the other hand, *bla*_{CTX-M-2} was also detected in 15 isolates (16.48%), being them chicken meat (n = 7), human (n = 6) and pork (n = 2). The CTX-M-8 and CTX-M-14 coding genes were present in eight and five human isolates, and two and one chicken meat isolates,

respectively. The CTX-M-24 (n = 4), CTX-M27 (n = 3) and CTX-M-3 (n = 1) coding genes were present only in human isolates.

In this work, 52 plasmid incompatibility groups belong to the p0111, IncF, IncI1, and IncN families. In human isolates, the most frequent pMLST were IncI1[ST-113] (n=9), IncF[F-: A-: B-] (n=7), IncF[F1: A2: B20] (n=5), IncF[F48: A1: B49] (n=5) and p0111 (n=5). In chicken meat isolates, IncF[F18: A-: B1] (n=8), p0111 (n=7) and IncN [Unknown ST] (n=5) were the most frequent pMLST. In isolates of pork, the most frequent incompatibility groups were IncN[Unknown ST] (n=4) and IncF[F33: A-: B1] (n=3).

In total, 40 sequence types (STs) were found, the most observed were the ST131 (n = 12), ST38 (n = 8), ST648 (n = 7), and ST354 (n = 6). Some STs were detected in more than one source, demonstrating a genetic relationship between these isolates, mainly between humans and chicken meat. The ST38, ST131, ST354, and ST1196 were found in both urine and chicken meat strains in the respective quantities of 5 and 3, 12 and 1, 4 and 3 and 1 and 1. The ST410 was the only observed in urine (n = 1) and pork (n = 1) strains. The ST117 was present in the three sources studied, with two strains from urine, one from chicken meat and pork.

The clonal relationship between the isolates in this study and other isolates in Brazil can be seen in **Figure 2** (<https://microreact.org/project/2mKg54AHdWj5xdJ5VFejY8>). It is important to highlight the clustering of ST131 strains in this study with the *E. coli* strain isolated from human urine in the United Kingdom (UK), in 2003, indicating a possible origin of these clones in Brazil, which acquired new plasmids such as the one that carries CTX -M-55¹⁴.

DISCUSSION

This study presents the first reports of *E. coli* ST131-C1-M27 in human infection and CTX-M-24-positive *E. coli* ST354 from ITU, in Brazil. In Latin America CTX-M-producing *E. coli* are endemic. Our data show a wide distribution of these isolates belonging to the international clones in livestock and the community. The extensive presence of CTX-M enzyme-producing strains in several sources raises the hypothesis that the spread occurs with greater frequency and efficiency, especially among enterobacteria⁹.

E. coli ST131 globally known and is related to the spread of resistance genes, including specific CTX-M coding genes¹⁵. Recent studies have shown that ST131 is rare among animal isolates, becoming almost exclusively a human pathogen, as demonstrated by our results, where ST131 is predominantly found in strains of human urine¹⁶. The subclade C2 is associated with *bla*_{CTX-M-15}

that can be carried by different groups of plasmids¹⁷. Here we also observe that all *bla*_{CTX-M-15} are involved with the incompatibility group IncF. In a study by Peirano et al. (2020), it was shown that clade C was related to the highest rates of UTI, with subclade C2 being the most common and associated with incompatibility group IncFII¹⁸. Besides, CTX-M-15-producing *E. coli* ST131 has already been shown to be involved in outbreaks in health institutions and is the most prevalent ESBL-producing *E. coli* worldwide¹⁹.

The CTX-M-27-producing ST131-C1 has been considered a new epidemic clone, and there have been no reports of human infections so far, in Brazil. Clade C1-M27 is associated with CTX-M-27 and was first observed as colonizing children in France in 2012. Recent studies suggest that the subclade C1-M27 was recently selected since SNPs have a smaller difference between isolates of this same subclade than SNPs of isolates of subclade C2 and A. In addition, the plasmid predominantly involved with the dissemination of *bla*_{CTX-M-27} is IncF[F1:A2:B20], as found in our study. Resistance to fluoroquinolones, macrolides, tetracyclines, aminoglycosides, and sulfonamides appears to be part of the profile of C1-M27 isolates^{20,21}.

The CTX-M-14 and CTX-M-24 enzymes belong to the CTX-M-9 group. Although the first one is widely distributed worldwide, especially in China, South-East Asia, Japan, South Korea, and Spain, microorganisms producing CTX-M-24 remain relatively rare, reported with greater incidence in countries such as Peru and Bolivia^{18,22,23}. This study found an important association between CTX-M-24 and *E. coli* ST354 detected in two human isolates, never before reported in UTI in Brazil. In a study by Dagher et al. (2018), ST354 isolates were positive to *bla*_{CTX-M-24} and resistant to ciprofloxacin, associated with extra-intestinal infections, animals and humans, reinforcing the zoonanthroponotic hypothesis of these clones²⁴.

ESBL type CTX-M-2 and CTX-M-55 are frequently found, and their coding genes are spread in several ways. Some studies suggest that the plasmid IncF[F33: A-: B-] is involved in disseminating these genes, which may explain the coexistence of these two genes in two strains belonging to ST1725 isolated from urine samples²⁵. Although another strain of *E. coli* ST6448 isolated from chicken meat also showed the coexistence of *bla*_{CTX-M-2} and *bla*_{CTX-M-5}, the plasmids that carried them belonged to IncF [F24: A-: B73] and IncII [ST -131], respectively. In the last ten years, IncII-type plasmids have had a high spread, mainly in animal reservoirs. There are reports of *bla*_{CTX-M-2}, *bla*_{CTX-M-8} and *bla*_{CTX-M-55} genes frequently found on IncI plasmids from

E. coli isolated from chickens and pigs several countries, such as China, France, the United States of America, and the United Kingdom^{26–28}.

The international clone ST117, found in the three different sources of this study, is often found in chicken meats and pork, and it is also associated with human infections. Studies have already reported the multiple resistance profile of ST117 and associated it with CTX-M-55 expression, consistent with our results^{29,30}. Likewise, ST38 is also widely found in chickens and humans, worldwide, and is related to several ESBL genes, such as *bla*_{CTX-M-14}, *bla*_{CTX-M-27}, and *bla*_{CTX-M-55}. One of the hypotheses for the successful dissemination of these genes among the *E. coli* clones is that the families of plasmids IncI1 and IncF are important vectors for disseminating *bla*_{CTX-M}. In China, South Korea, and Japan, studies suggest an epidemic of *bla*_{CTX-M} genes carried by plasmids IncI1, IncF[F33: A-: B-], IncF[F46: A-: B20] and IncF[F18: A-: B1], found in cattle, pigs, chickens, pets and humans^{31–33}.

In conclusion, *E. coli* carrying *bla*_{CTX-M} genes from different sources seem to be related to the spread of internationally known clones (ST354, ST131, ST117, ST38). Some clones associated with some CTX-M variants are more prevalent in some sources than others does not exclude the possibility that new clones are entering and establishing themselves in different niches, as shown in this study. Thus, novel studies should continue to be carried out with more samples and sources to understand further the dynamics of dissemination, shift, and establishment of ESBL-producing *E. coli* clones at the interface between animal sources and human health.

MATERIAL AND METHODS

Study population

During a surveillance study from June 2016 to May 2019, a collection of 22.698 *E. coli* strains was obtained from urine culture of community women patients assisted by public health services, being 1.389 positive to ESBL production. Concomitantly, from January to May 2019, 100 *E. coli* strains were isolated from chicken meat (n=50), and pork (n=50) bought at markets and butcher shops. Markets and butcher shops were selected according to public health services, all located in different regions from Londrina, a city located in Paraná state, South Brazil.

ERIC-PCR was performed for all the strains that showed positive ESBL and, through the similarity profile, 91 *E. coli* strains were selected for this study, being 59 isolated from urine culture and 32 isolated from chicken meat (n=24) and pork (n=8). The study was approved by

the Ethics and Research Committee of the State University of Londrina CAAE 56869816.0.0000.5231.

Microbiological methods

Urine collected from women patients was inoculated on CHROMagar (Becton Dickinson, Heidelberg, Germany) and MacConkey (Merck, Darmstadt, Germany) plates using a calibrated inoculating loop with a capacity of 10 μ l and incubated at 37°C for 24h.

The samples of chicken meat and pork were dipped in Brain Heart Infusion broth (Oxoid) with cefotaxime (4 μ g / mL), ciprofloxacin (4 μ g / mL), and both (Sigma-Aldrich, Munich, Germany) to selected resistant *E. coli* strains. After incubation, the solution was inoculated in the same way used for urine samples. All the isolates were stored in Tryptic Soy Broth (TSB) with 15% glycerol (–20°C).

The identification and bacterial susceptibility were performed by the automated VITEK[®] 2 system, using the VITEK[®] 2 AST 239 card and the VITEK[®] 2 GN ID card (BioMérieux, USA). The bacterial susceptibility was tested for 14 antibiotics: ampicillin, amoxicillin/clavulanate, ceftriaxone, cefepime, ertapenem, meropenem, nalidixic acid, ciprofloxacin, norfloxacin, gentamicin, amikacin nitrofurantoin, trimethoprim-sulfamethoxazole, and piperacillin-tazobactam. The CLSI 2020 (Clinical and Laboratory Standards Institute) criteria were used for interpretation³⁴. *E. coli* ATCC[®]25922 strain was used as quality control.

ERIC-PCR

ESBL-producing isolates were subjected to Enterobacterial Repetitive Intergenic Consensus (ERIC-PCR), by Versalovic et al. (1991)³⁵. Analysis of genomic fingerprinting was performed using GelJ v.2.0 software by the Dice similarity method (HERAS et al., 2015)³⁶. Strains were considered genetically related if the similarity index was ≥ 85 %.

DNA isolation and whole-genome sequencing

For DNA extraction, strains were grown on Mueller-Hinton Agar overnight at 37 °C. Subsequently, a single colony was inoculated in 2 mL of Luria-Bertani broth for 12 hours at 37 °C. The suspension was used to continue extraction and purification by the DNA extraction kit (Invitrogen, Carlsbad, CA). The extracted DNA was quantified by Qubit dsDNA (double-stranded DNA) BR assay kit (Invitrogen, Carlsbad, CA). After quantification, the DNA was used to construct a paired-end library (150 bp), sequenced using the NextSeq platform (Illumina). The instructions of each manufacturer were followed in all steps.

Bioinformatic analysis

Genome quality filter and assemblies were performed by the CLC Genomics Workbench version 7.0 (Aarhus, Denmark). Multilocus sequence type (MLST), resistome, and virulome were identified using MLST v2.0 (Larsen et al., 2012), ResFinder v3.1 (Bortolaia et al., 2020), VirulenceFinder v2.0, (Joensen et al., 2014), PlasmidFinder v2.1 (Carattoli et al., 2014), FimTyper v1.0 (Roer et al., 2017) and SerotypeFinder v.2.0 (Joensen et al., 2015), respectively. The BacMet database (Pal et al., 2013) was used to identify biocides and heavy metal (HM)^{31,37-43}. The Enterobase (<https://enterobase.warwick.ac.uk/>) was used to create a single nucleotide polymorphisms (SNPs) project to strains that showed the same STs genomes were aligned against genomes of other Brazilian studies.

REFERENCES

1. Subashchandrabose, S. & Mobley, H. L. T. Virulence and fitness determinants of uropathogenic *Escherichia coli*. *Microbiol. Spectr.* **3**, 235–261. doi:10.1128/microbiolspec.UTI-0015-2012 (2015).
2. Poirel, L. et al. Antimicrobial resistance in *Escherichia coli* in antimicrobial resistance in bacteria from livestock and companion animals. *American Society of Microbiology* 289–316. doi:10.1128/microbiolspec.ARBA-0026-2017 (2018).
3. Allcock, S. et al. Antimicrobial resistance in human populations: challenges and opportunities. *Glob. Heal. Epidemiol. Genomics* **2**. doi:10.1017/ghg.2017.4 (2017).
4. Reid, C. J., McKinnon, J. & Djordjevic, S. P. Clonal ST131-H22 *Escherichia coli* strains from a healthy pig and a human urinary tract infection carry highly similar resistance and virulence plasmids. *Microb. Genomics* **5**. doi: 10.1099/mgen.0.000295 (2019).
5. Clifford, K. et al. Antimicrobial resistance in livestock and poor quality veterinary medicines. *Bull. World Health Organ.* **96**, 662–664. doi: 10.2471/BLT.18.209585 (2018).
6. Gozi, K. S. et al. Dissemination of multidrug-resistant commensal *Escherichia coli* in feedlot lambs in southeastern Brazil. *Front. Microbiol.* **10**. doi: 10.3389/fmicb.2019.01394 (2019).
7. Koga, V. L. et al. Characterization of CMY-2-type beta-lactamase-producing *Escherichia coli* isolated from chicken carcasses and human infection in a city of South Brazil. *BMC Microbiol.* **19**, 1–9. doi: 10.1186/s12866-019-1550-3 (2019).
8. Paphitou, N. I. Antimicrobial resistance: action to combat the rising microbial challenges. *Int. J. Antimicrob. Agents* **42**, S25–S28. doi: 10.1016/j.ijantimicag.2013.04.007 (2013).
9. Cyoia, P. S. et al. Distribution of ExPEC virulence factors, blaCTX-M, fosA3, and mcr-1 in *Escherichia coli* isolated from commercialized chicken carcasses. *Front. Microbiol.* **10**, 1–9. doi: 10.3389/fmicb.2018.03254 (2019).
10. Daga, A. P. et al. *Escherichia coli* bloodstream infections in patients at a university hospital:

virulence factors and clinical characteristics. *Front. Cell. Infect. Microbiol.* **9**. doi: 10.3389/fcimb.2019.00191 (2019).

11. Irrgang, A. *et al.* CTX-M-15-producing *E. coli* isolates from food products in Germany are mainly associated with an IncF-type plasmid and belong to two predominant clonal *E. coli* lineages. *Front. Microbiol.* **8**. doi: 10.3389/fmicb.2017.02318 (2017).
12. Gonçalves, L. F. *et al.* Multidrug resistance dissemination by extended-spectrum β -lactamase-producing *Escherichia coli* causing community-acquired urinary tract infection in the Central-Western Region, Brazil. *J. Glob. Antimicrob. Resist.* **6**, 1–4. doi: 10.1016/j.jgar.2016.02.003 (2016).
13. Silva, N. *et al.* Genetic characterisation of extended-spectrum β -lactamases in *Escherichia coli* isolated from retail chicken products including CTX-M-9 containing isolates: a food safety risk factor. *Br. Poult. Sci.* **53**, 747–755. doi: 10.1080/00071668.2012.740554 (2012).
14. Forde, B. M. *et al.* The complete genome sequence of *Escherichia coli* EC958: A high quality reference sequence for the globally disseminated multidrug resistant *E. coli* O25b:H4-ST131 clone. *PLoS One* **9**. doi:10.1371/journal.pone.0104400 (2014).
15. Kondratyeva, K., Salmon-Divon, M. & Navon-Venezia, S. Meta-analysis of pandemic *Escherichia coli* ST131 plasmidome proves restricted plasmid-clade associations. *Sci. Rep.* **10**, 1–11. doi: 10.1038/s41598-019-56763-7 (2020).
16. Peirano, G. *et al.* Trends in population dynamics of *Escherichia coli* sequence type 131, Calgary, Alberta, Canada, 2006–2016. *Emerg. Infect. Dis.* **26**, 2907–2915. doi: 10.12688/f1000research.10609.1 (2020).
17. Coque, T. M. *et al.* Dissemination of clonally related *E. coli* strains expressing ESBL CTX-M-15. *Emerg. Infect. Dis.* **14**, 195–200. doi:10.3201/eid1402.070350 (2008).
18. Peirano, G. & Pitout, J. D. D. Extended-spectrum β -lactamase-producing *Enterobacteriaceae*: update on molecular epidemiology and treatment options. *Drugs* **79**, 1529–1541. doi: 10.1007/s40265-019-01180-3 (2019).
19. Nicolas-Chanoine, M. H. *et al.* Intercontinental emergence of *Escherichia coli* clone O25:H4-T131 producing CTX-M-15. *J. Antimicrob. Chemother.* **61**, 273–281. doi: 10.1093/jac/dkm464 (2008).
20. Birgy, A. *et al.* Independent host factors and bacterial genetic determinants of the emergence and dominance of *Escherichia coli* sequence type 131 CTX-M-27 in community pediatric cohort study 1–10. doi: 10.1128/AAC.00382-19 (2019).
21. Fernandes, M. R. *et al.* Emergence of CTX-M-27-producing *Escherichia coli* of ST131 and clade C1-M27 in an impacted ecosystem with international maritime traffic in South America. *J. Antimicrob. Chemother.* **75**, 1647–1649. doi: 10.1093/jac/dkaa069 (2020).
22. Song, J., Oh, S. S., Kim, J. & Shin, J. Extended-spectrum β -lactamase-producing *Escherichia coli* isolated from raw vegetables in South Korea. *Sci. Rep.* **10**, 1–7. doi: 10.1038/s41598-020-76890-w (2020).
23. Delgado, D. Y. C., Barrigas, Z. P. T., Astutillo, S. G. O., Jaramillo, A. P. A. & Ausili, A. Detection and molecular characterization of β -lactamase genes in clinical isolates of Gram-negative bacteria in Southern Ecuador. *Brazilian J. Infect. Dis.* **20**, 627–630. doi: 10.1016/j.bjid.2016.07.001 (2016).
24. Dagher, C. *et al.* Molecular characterization of carbapenem resistant *Escherichia coli* recovered from a tertiary hospital in Lebanon. *PLoS One* **13**, 1–13. doi: 10.1371/journal.pone.0203323 (2018).

25. Cunha, M. P. V, Lincopan, N., Cerdeira, L. & Esposito, F. Coexistence of CTX-M-2, CTX-M-55, CMY-2, FosA3 and QnrB19 in extra-intestinal pathogenic *Escherichia coli* from poultry in Brazil. *Antimicrob. Agents Chemother.* **1-3** (2017)
26. Song, J., Oh, S. S., Kim, J., Park, S. & Shin, J. Clinically relevant extended-spectrum β -lactamase-producing *Escherichia coli* isolates from food animals in South Korea. *Front. Microbiol.* **11**, 1–9. doi: 10.3389/fmicb.2020.00604 (2020).
27. Castellanos, L. R. *et al.* High heterogeneity of *Escherichia coli* sequence types harbouring ESBL/AmpC genes on IncI1 plasmids in the Colombian poultry chain. *PLoS One* **12**, 1–15. doi: 10.1371/journal.pone.0170777 (2017).
28. Ferreira, J. C., Penha Filho, R. A. C., Andrade, L. N., Berchieri Junior, A. & Darini, A. L. C. Evaluation and characterization of plasmids carrying CTX-M genes in a non-clonal population of multidrug-resistant *Enterobacteriaceae* isolated from poultry in Brazil. *Diagn. Microbiol. Infect. Dis.* **85**, 444–448. doi: 10.1016/j.diagmicrobio.2016.05.011 (2016).
29. Cormier, A. *et al.* Diversity of CTX-M-positive *Escherichia coli* recovered from animals in Canada. *Vet. Microbiol.* **231**, 71–75. doi: 10.1016/j.vetmic.2019.02.031 (2019).
30. Norizuki, C. *et al.* Detection of *Escherichia coli* producing CTX-M-1-group extended-spectrum β -lactamases from pigs in Aichi Prefecture, Japan, between 2015 and 2016. *Jpn. J. Infect. Dis.* **71**, 33–38. doi: 10.7883/yoken.JJID.2017.206 (2018).
31. Lupo, A., Saras, E., Madec, J. Y. & Haenni, M. Emergence of bla CTX-M-55 associated with fosA, rmtB and mcr gene variants in *Escherichia coli* from various animal species in France. *J. Antimicrob. Chemother.* **73**, 867–872. doi: 10.1093/jac/dkx489 (2018).
32. Fernandes, M. R., Sellera, F. P., Moura, Q., Souza, T. A. & Lincopan, N. Draft genome sequence of a CTX-M-8, CTX-M-55 and FosA3 co-producing *Escherichia coli* ST117/B2 isolated from an asymptomatic carrier. *J. Glob. Antimicrob. Resist.* **12**, 183–184. doi: 10.1016/j.jgar.2018.01.015 (2018).
33. Xia, L. *et al.* Prevalence of ST1193 clone and IncI1/ST16 plasmid in *E. coli* isolates carrying blaCTX-M-55 gene from urinary tract infections patients in China. *Sci. Rep.* **7**, 1–8. doi: 10.1038/srep44866 (2017).
34. Abmm, D., Tamma, D., Kirn, J. & Cullen, S. K. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. *CLSI Suppl. M100* Wayne, PA, (2020).
35. Versalovic, J., Koeuth, T., Lupski, J. R. & Plaza, O. B. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. *Cell* **19**, 6823–6831. doi: 10.1093/nar/19.24.6823 (1991).
36. Heras, J. *et al.* GelJ - a tool for analyzing DNA fingerprint gel images. *BMC Bioinformatics* **16**, 1–8. doi: 10.1186/s12859-015-0703-0 (2015).
37. Larsen, M. V. *et al.* Multilocus sequence typing of total-genome-sequenced bacteria. *J. Clin. Microbiol.* **50**, 1355–1361. doi: 10.1128/JCM.06094-11 (2012).
38. Bortolaia, V. *et al.* ResFinder 4.0 for predictions of phenotypes from genotypes. *J. Antimicrob. Chemother.* **75**, 3491–3500. doi: 10.1093/jac/dkaa345 (2020).
39. Kleinheinz, K. A., Joensen, K. G. & Larsen, M. V. Applying the ResFinder and VirulenceFinder web-services for easy identification of acquired antibiotic resistance and *E. coli* virulence genes in

bacteriophage and prophage nucleotide sequences . *Bacteriophage* **4**, e27943. doi: 10.4161/bact.27943 (2014).

40. Carattoli, A. *et al.* In Silico detection and typing of plasmids using plasmidfinder and plasmid multilocus sequence typing. *Antimicrob. Agents Chemother.* **58**, 3895–3903. doi: 10.1128/AAC.02412-14 (2014).
41. Roer, L. *et al.* Development of a web tool for *Escherichia coli* subtyping based on fimh alleles. *J. Clin. Microbiol.* **55**, 2538–2543. doi: 10.1128/JCM.00737-17 (2017).
42. Joensen, K. G., Tetzschner, A. M. M., Iguchi, A., Aarestrup, F. M. & Scheutz, F. Rapid and easy in silico serotyping of *Escherichia coli* isolates by use of whole-genome sequencing data. *J. Clin. Microbiol.* **53**, 2410–2426. doi: 10.1128/JCM.00008-15 (2015).
43. Pal, C., Bengtsson-Palme, J., Rensing, C., Kristiansson, E. & Larsson, D. G. J. BacMet: Antibacterial biocide and metal resistance genes database. *Nucleic Acids Res.* **42**, 737–743. doi: 10.1093/nar/gkt1252 (2014)

ACKNOWLEDGEMENTS

The authors would like to thank the financial support of the Bill and Melinda Gates Foundation’s Grand Challenges Explorations Brazil – New Approaches to characterize the global burden of antimicrobial resistance (OPP1193112), the Research Support Facilities Center of the State University of São Paulo (CEFAP-USP), Institute of Biomedical Sciences of State University of São Paulo (ICB-USP) and Master’s program Clinical and Laboratory Pathophysiology of the State University of Londrina.

AUTHOR INFORMATION

Affiliations

Laboratory of Clinical Microbiology, Department of Pathology, Clinical and Toxicological Analysis, Health Sciences Center, State University of Londrina, Londrina, Brazil

João Gabriel Material Soncini

Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia

Louise Cerdeira

Department of Microbiology, Biological Science Center, State University of Londrina, Londrina, Brazil

Vanessa Lumi Koga

Laboratory of Clinical Microbiology, Department of Pathology, Clinical and Toxicological Analysis, Health Sciences Center, State University of Londrina, Londrina, Brazil

Ariane Tiemy Tizura

Department of Microbiology, Biological Science Center, State University of Londrina, Londrina, Brazil

Gerson Nakazato

Department of Microbiology, Biological Science Center, State University of Londrina, Londrina, Brazil

Renata Katsuko Takayama Kobayashi

Department of Health Science, Health and Biological Science Center, Federal Rural University of Semi-Arid, Mossoró, Brazil.

Caio Augusto Martins Aires

Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Brazil

Nilton Lincopan

Laboratory of Clinical Microbiology, Department of Pathology, Clinical and Toxicological Analysis, Health Sciences Center, State University of Londrina, Londrina, Brazil

Eliana Carolina Vespero

Data availability

Draft whole-genome assembly was deposited in GenBank under the BioProject PRJNA578368 and SRA SRP226200. The data of the figures can be accessed in Figshare (<https://doi.org/10.6084/m9.figshare.13471044.v1>).

ETHICS DECLARATIONS

Competing interests

The authors declare no competing interests.

Ethical approval

The study was approved by the Ethics and Research Committee of the State University of Londrina CAAE 56869816.0.000.5231.




Figure 02 – Phylogenomic SNP tree and *E. coli* dissemination map in Brazil.